Business Context and Reporting Period
This Form 8-K is a current report filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) on June 3, 2025. The registrant is incorporated in Delaware and maintains its principal executive offices in Kuala Lumpur, Malaysia. The report discloses a specific corporate event under Item 8.01 (Other Events).
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial data disclosed relates to a dividend declaration:
- Dividend Amount: $0.15 per share.
- Security Type: 6% Convertible Exchangeable Preferred Stock (Trading Symbol: CYCCP).
- Record Date: July 21, 2025.
- Payment Date: August 1, 2025.
Material Changes
The filing reports the Board of Directors' declaration of a quarterly cash dividend. No material changes to revenue, operations, or capital structure other than this dividend obligation are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a notification of the dividend declaration.
Investor Verification Checklist
- Verify the total number of outstanding shares of 6% Convertible Exchangeable Preferred Stock to calculate the total cash outflow for the dividend.
- Confirm the company's current liquidity position to ensure it can meet the August 1, 2025, payment obligation.
- Check the company's recent 10-Q or 10-K filings for context on cash flow and profitability, as this 8-K does not provide them.
- Note the discrepancy between the requested company name ("Bio Green Med Solution, Inc.") and the actual registrant ("Cyclacel Pharmaceuticals, Inc.") in the source text.